Day 1 of Cebu’s COVID-19 vaccination: 50 to 70 frontliners from Sotto receive Sinovac

Morexette Marie B. Erram 03/04/2021

CEBU CITY, Philippines  –– Cebu on Thursday, March 4, has officially kicked off its initial coronavirus disease 2019 (COVID-19) vaccine rollout, barely a year after the first confirmed cases of the infection were reported in the country.…

PGH director is PH’s first Covid-19 vaccine recipient

Krissy Aguilar - Reporter / @KAguilarINQ 03/01/2021

MANILA, Philippines — The Philippines has given its first Covid-19 vaccine to Philippine General Hospital (PGH) Director Dr. Gerardo “Gap” Legaspi. Legaspi received the vaccine developed by China’s Sinovac Biotech on Monday at the PGH. PGH nurse…

Hubris, ineptness, and the vaccine program

Solita Callas-Monsod - @inquirerdotnet 02/27/2021

Food and Drug Administration (FDA) Director General Eric Domingo showed a lot of balls when he gave Sinovac’s CoronaVac the green light for emergency use authorization (EUA), but with a recommendation that it not be used for…

Sinovac vaccine’s 50% efficacy is acceptable—DOST

Darryl John Esguerra - Reporter / @DJEsguerraINQ 12/24/2020

MANILA, Philippines — The 50% efficacy of the COVID-19 vaccine of China’s Sinovac Biotech is “acceptable” as it is within the World Health Organization’s (WHO) minimum requirement, the Department of Science and Technology (DOST) said on Thursday.…

Brazil halts trials of Chinese Covid-19 vaccine

11/10/2020

Rio de Janeiro, Brazil—Brazil’s health regulator said Monday it had suspended clinical trials of a Chinese-developed Covid-19 vaccine after an “adverse incident” involving a volunteer recipient, a blow for one of the most advanced vaccine candidates. The…

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.